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Ⅰ．Introduction
 Hepatocellular carcinoma （HCC） represents the 
sixth most common cancer in the world and is the 
third most common cause of cancer-related deaths
［1］. In Japan, more than 30,000 patients with HCC 
die every year［2］. Of importance, advanced HCC with 
extrahepatic spread and/or major vascular invasion has 
a very poor prognosis. Sorafenib, an oral multikinase 
inhibitor, blocks tumor cell proliferation by targeting 
Raf/MEK/ERK signaling and also exerts an anti-
angiogenic effect by targeting tyrosine kinase receptors, 
such as vascular endothelial growth factor receptor and 
platelet derived growth factor receptor［3］. Although 
sorafenib has been utilized as a standard medical 
treatment for patients with advanced HCC［4,5］, its 
survival benefit is modest and still unsatisfactory. 
 Recent advancements in stem cell biology have 
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SUMMARY
Recent advances in stem cell biology and technologies have enabled the identification of a minor 
component of tumorigenic cells, termed cancer stem cells or tumor-initiating cells （TICs）, in a variety 
of cancers, including hepatocellular carcinoma （HCC）. TICs play a central role in tumor development, 
metastasis, and recurrence. The analyses of TIC characteristics have revealed the molecular machinery 
and signaling pathways involved in maintaining them. Although the inhibitors of these molecules and 
signaling pathways are considered to be promising as TIC-targeting drugs, the establishment of novel 
therapeutic approaches for the eradication of these cells is yet to be accomplished. In this study, the 
authors revealed that polycomb group （PcG） proteins play an important role in the maintenance of 
tumor-initiating HCC cells and that short-hairpin RNA and small molecule compounds inhibiting PcG 
proteins markedly interfere with the tumorigenicity of TICs. Next, we examined whether existing medical 
drugs could exert their anti-TIC function to promptly apply the research outcomes in clinical settings. 
Accordingly, we found that disulfiram （DSF）, a drug for alcohol dependence, impaired the tumorigenicity 
of tumor-initiating HCC cells through the activation of the ROS-p38 pathway and the down-regulation of 
Glypican3  but not through the inhibition of aldehyde dehydrogenase. These results indicate that DSF is a 
promising therapeutic agent for the eradication of TICs. Based on these findings, a phase I/II clinical trial 
of DSF was started in patients with advanced HCC.
　Key words:  Hepatocellular carcinoma, cancer stem cell, tumor-initiating cell, polycomb group proteins, 
ROS-p38 pathway
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enabled the identification and characterization of stem 
cells in a variety of tissues and organs. Moreover, it has 
been documented that solid tumors such as breast cancer 
and colon cancer contain a small subset of tumorigenic 
cells, which can generate new tumors in xenograft 
transplantation［6,7］. This minor population of cells, 
termed cancer stem cells （CSCs） or tumor-initiating 
cells （TICs）, possesses stem cell-like properties and 
contributes to a hierarchical structure containing varied 
progenies in a similar fashion to normal stem cells. 
Both normal stem cells and TICs share a largely similar 
surface marker and a molecular machinery controlling 
self-renewal and differentiation. To explain tumor 
heterogeneity, two general theories were proposed［8］. 
The hierarchical model assumes that TICs represent a 
biologically distinct subset within the total malignant 
cell population. It is relevant to the designation of 
malignant tumor-propagating cells as TICs, although it 
is not necessary that TICs are functionally or genetically 
homogeneous. According to this model, a pool of TICs 
can only be maintained by cells that have both TIC 
potential and the ability to give rise to progeny with a 
self-limited proliferative capacity. On the other hand, 
the stochastic model assumes that every cell comprising 
a tumor has tumor-initiating potential and that their 
different activities are determined by some stochastically 
varying intrinsic factor. The recent successful detection 
and characterization of TICs in a variety of tumors 
appears to support the hierarchical carcinogenesis theory
［9］. 
Ⅱ．Identification of tumor-initiating HCC cells
 Side population （SP） cell sorting was developed to 
enrich hematopoietic stem cells in murine bone marrow
［10］. The SP phenotype is determined by the ability 
to efflux the dye Hoechst 33342 through an adenosine 
triphosphate （ATP）-binding cassette （ABC） membrane 
transporter［11］. This technique has also been widely 
applied to detect TICs in various cancer cell lines［12］. 
In our study, only 0.25％-0.80％ of HCC cells exhibit 
the SP phenotype, and these cells show a marked tumor-
initiating capacity in xenotransplantation assays using 
immunodeficient mice［13］. One thousand SP cells were 
enough to generate tumors in xenotransplantation, while 
at least 1 × 106 unsorted HCC cells were required for 
tumor formation, suggesting that TICs are enriched by 
SP cell sorting by at least a 1000-fold （Fig. 1A）. These 
results indicated that the frequency of HCC SP cells was 
less than 1％. Therefore, this minority population of SP 
cells but not non-SP cells might possess tumorigenic 
potential in these HCC cells.
 More recently, tumor-initiating HCC cells were 
successfully identified by some cell surface antigens. 
HCC cells positive for markers, including CD133
［14］, CD90［15］, CD44［16］, epithelial cell adhesion 
molecule （EpCAM）［17］,  OV6［18］,  and CD24
［19］, were shown to function as TICs in HCC （Table 
1）. Of interest, it has been reported that EpCAM and 
Fig. 1 Identification and characterization of SP cells in HCC. 
（A） Flow cytometry analysis with Hoechst 33342 
staining demonstrated that Huh7 cells included 0.25％ 
of SP cells. Only 1 × 103 SP cells purified from 
Huh7 cells could develop tumors in the NOD/SCID 
xenograft transplant assay. （B） Immunocytochemical 
analyses of BMI1 expression in SP and non-SP cells 
purified from Huh7 cells.
A
B
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 PcG complexes are the key regulators of epigenetic 
cellular memory. They establish and maintain cellular 
identities during embryogenesis, development, and 
tumorigenesis［23］. PcG complexes can be functionally 
separated into at least two distinct complexes: a 
maintenance complex, polycomb repressive complex 
（PRC） 1, and an initiation complex, PRC2. Bmi1, one 
of the components of PRC1, is essential for maintaining 
the self-renewal capability of somatic stem cells 
including hepatic stem/progenitor cells［24］. On the 
other hand, the overexpression of Bmi1 in hepatic stem/
progenitor cells augments their self-renewal capability 
and induces tumor development in mice［25］. Of note is 
that the expression levels of BMI1 in HCC cell lines are 
well correlated with the proportion of tumor-initiating 
SP cells （Fig. 1B）［26］. Furthermore, the levels of 
BMI1 expression in HCC are well correlated with the 
progression and prognosis of the disease［27］. These 
findings suggest that Bmi1 regulates the self-renewal 
of both normal stem cells and TICs by repressing the 
transcription of negative regulator genes for stem cell 
maintenance, such as Ink4a and Arf［28］.
 Ezh2, one of the components of PRC2, shows 
catalytic activity specific for the trimethylation of 
CD90 are independently expressed in primary HCC
［20］. The microarray analysis of sorted cells suggested 
that EpCAM＋ cells showed features of epithelial 
cells, whereas CD90＋ cells had features of vascular 
endothelial cells. HCCs containing EpCAM＋ cells are 
associated with poorly differentiated pathology and a 
high serum level of alpha-fetoprotein （AFP）, whereas 
the CD90＋ HCCs are associated with a high incidence 
of distant metastasis. Taken together, TICs might 
possess variable antigenic and functional properties and 
represent a heterogeneous population of cells.
Ⅲ ．Maintenance machinery of tumor-initiating 
HCC cells
 Cancer-related molecules and signaling pathways, 
such as the Polycomb-group （PcG） gene products, 
Wnt signaling, and PI3K/AKT/mTOR pathways, play 
an important role in the maintenance or augmentation 
of the self-renewal capability of tumor-initiating HCC 
cells （Table 2）［21,22］. To develop novel therapeutic 
approaches for the eradication of TICs, understanding 
the molecular mechanisms underlying the maintenance 
of TICs is of importance. 
Table 1　Identification of tumor-initiating HCC cells
Phenotype Cell line/Primary tumor Reference
Side population Cell line Chiba et al. Hepatology, 44: 240, 2006.
CD133＋ Cell line Ma et al. Gastroenterology, 132: 2542, 2007.
CD133＋ALDH＋ Cell line Ma et al. Mol Cancer Res, 8: 1146, 2008.
CD90＋CD44＋ Cell line/Primary tumor Yang et al. Cancer Cell, 13: 153, 2008.
EpCAM＋ Cell line/Primary tumor Yamashita et al. Gastroenterology, 136: 1012, 2009.
CD133＋CD44＋ Cell line Zhu et al. Int J Cancer, 126: 2067, 2010.
CD24＋ Cell line/Primary tumor Lee et al. Cell Stem Cell, 9: 50, 2011.
Table 2　Molecular machinery for the maintenance of tumor-initiating HCC cells
Molecule/signaling Reference
Wnt/β-catenin Yamashita et al. Cancer Res, 67: 10831, 2007.
BMI1 Chiba et al. Caner Res, 68: 7742, 2008.
Akt/PKB Ma et al. Oncogene, 27: 1749, 2008.
miR-181 Ji et al. Hepatology, 50: 472, 2009.
miR-130b Ma et al. Cell Stem Cell, 7: 694, 2010.
NANOG （STAT-3） Lee et al. Cell Stem Cell, 9: 50, 2011.
IL-8 Tang et al. Hepatology, 55: 807, 2012.
EZH2 Chiba et al. Int J Cancer, 130: 2557, 2012.
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histone H3 at lysine 27 （H3K27）. Similar to BMI1, 
EZH2 is also overexpressed in tumor-initiating HCC 
cells［29］. We previously reported that Ezh2 tightly 
regulates the self-renewal and differentiation of murine 
hepatic stem/progenitor cells［30］. In addition, loss-
of-function assays of EZH2 using short-hairpin 
RNA and the pharmacological inhibition of EZH2 
by an S-adenosylhomocysteine hydrolase inhibitor, 
3-deazaneplanocin A （DZNep）, showed that both 
EZH2 -knockdown and DZNep treatment decrease the 
number of TICs and impair their function （Fig. 2）［31］. 
These findings revealed that tumor-initiating HCC cells 
are highly dependent on EZH2 for their tumorigenic 
activity.
Ⅳ．Therapeutic approaches targeting liver TICs
 Although classical anticancer treatment such as 
chemotherapy and radiation therapy can eliminate 
proliferating cells in a tumor, TICs often exhibits 
resistance to these treatments［32,33］. The investigation 
of treatments targeting TICs has just started and the 
interference with their self-renewal, survival, migration, 
or invasion mechanisms are considered a possible 
strategy［34］. However, no effective therapy targeting 
TICs has been developed in HCC up to the present. We 
focused on existing medical drugs showing antitumor 
effects and examined whether these drugs could 
eliminate TICs.
a）Metformin
 Metformin is an oral antidiabetic drug for the 
treatment of type 2 diabetes mellitus［35］. This drug 
activates AMP-activated protein kinase （AMPK） 
and thereby contributes to a reduction in hepatic 
gluconeogenesis and an increase in glucose uptake in 
skeletal muscles［36］. Of interest, previous studies have 
suggested that metformin has an anti-cancer effect in 
various types of malignancies, including breast cancer 
and ovarian cancer, and even in HCC［37-39］. Various 
explanations for the anticancer action of metformin 
have been proposed, such as the activation of AMPK, 
the inhibition of insulin-like growth factor signaling, 
and the mTOR pathway［40］. We then examined 
whether metformin has direct effects on tumor-initiating 
HCC cells［41］. Sphere formation assays showed that 
metformin significantly suppressed both the sphere 
formation ability and the replating activity of tumor-
initiating HCC cells in a dose-dependent manner. In 
addition, metformin treatment reduced the number of 
EpCAM＋ and AFP＋ cells in primary spheres （Fig. 3）. 
This finding indicated that metformin impaired tumor-
initiating HCC cells and simultaneously promoted the 
differentiation toward non-TICs. 
Fig. 2 Flow cytometric analyses of EpCAM＋ cells. （A） 
Knockdown of EZH2  significantly decreased the 
EpCAMhigh fraction in HCC cells. （B） EpCAMhigh 
fraction was significantly decreased after DZNep 
treatment in HCC cells.
A
B
41Tumor-initiating cells in hepatocellular carcinoma: a possible therapeutic target
 mTOR signaling also makes a significant 
contribution to the maintenance of TICs in breast cancer 
and prostate cancer［42,43］. The aberrant activation of 
mTOR signaling was also observed in approximately 
50％ of patients with HCC［44,45］. We demonstrated 
that metformin treatment apparently inhibited the mTOR 
pathway by phosphorylating AMPK in tumor-initiating 
Huh7 cells but not Huh1 cells. This implies that 
metformin exerts its anti-TIC effect in either an AMPK/
mTOR pathway-dependent or -independent manner. 
Of interest, metformin was shown to cause cell cycle 
arrest by downregulating the expression of cyclin D1 
and/or upregulating the expression of cyclin-dependent 
kinase inhibitors such as p21Cip1 without inhibiting 
the mTOR pathway［46,47］. A recent study revealed a 
novel mechanism wherein metformin blocks glucagon-
dependent glucose output from hepatocytes by reducing 
cyclic AMP and protein kinase A levels［48］. Further 
analyses on the mechanisms of the anti-TIC activity of 
metformin are required.
 Given that the risk of HCC is significantly lower 
with metformin treatment than with sulphonylureas or 
insulin in patients with chronic liver disease［49］, it is 
further necessary to examine whether metformin can be 
used in elimination of TICs in HCC in clinical trials. 
b）Disulfiram
 For more than 50 years, disulfiram （DSF）, an 
irreversible inhibitor of aldehyde dehydrogenase, has 
been widely used in alcohol aversion treatment［50］. 
DSF and its metabolites have been shown to suppress 
ethanol metabolism mainly through the inhibition 
of cytosolic aldehyde dehydrogenase 1 （ALDH1） 
and mitochondrial ALDH2［51］. In addition, recent 
reports have shown that DSF possesses the potential 
to target multidrug resistance, angiogenesis, invasion, 
and proteasome［52］. Of interest, DSF inhibits the 
tumorigenicity of breast CSCs and enhances the 
cytotoxicity of anticancer drugs［53］.
 In this study, we first showed that DSF inhibited the 
sphere-forming ability of HCC cells and tumor growth 
in xenograft transplant experiments using non-obese 
diabetic/severe combined immunodeficient （NOD/
SCID） mice in a dose-dependent manner （Fig. 4）. Flow 
cytometric analysis revealed that the DSF treatment 
caused a significant decrease in the number of tumor-
Fig. 3 H&E staining and immunocytochemical analysis of 
spheres derived from EpCAM＋ cells. Immunostaining 
analysis showed that metformin treatment markedly 
decreased in a number of EpCAM＋ and AFP＋ cells in 
spheres.
Fig. 4 Tumorigenicity of HCC cells treated with DSF in 
vitro and in a xenograft transplantation model. （A） 
Sphere-forming ability was significantly impaired 
in DSF-treated HCC cells. （B） Tumor initiation 
and growth were apparently suppressed by the DSF 
treatment.
A
B
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inhibitor of the p38 kinase pathway largely restored the 
tumorigenicity of TICs. These findings indicate that the 
ROS-p38 MAPK pathway is directly associated with 
cell growth and the tumor-initiating capability of HCC 
cells. 
 Next, we performed microarray analyses using 
TICs treated with DSF or 5-fluorouracil （5-FU）. The 
gene set enrichment analysis results support the present 
biological findings and implicate the activation of p38 
in the anti-TIC activity of DSF. Importantly, the 23 
genes in the “liver cancer” category were significantly 
downregulated after DSF exposure, but none of them 
were significantly altered after the 5-FU treatment. 
We focused on one of these genes, GPC3 , because 
the increased expression of GPC3 was correlated 
with a poor prognosis among HCC patients［59,60］. 
The knockdown of GPC3  significantly reduced both 
the sphere-forming ability and replating activity. 
Additionally, the immunocytochemical analyses of the 
large spheres showed a decrease in the number of cells 
expressing AFP or EpCAM. Taken together, it appears 
that DSF suppresses the tumorigenicity of tumor-
initiating HCC cells, in part, by downregulating GPC3  
expression. 
initiating HCC cells expressing stem cell markers such 
as CD133 and EpCAM. Given that the knockdown of 
ALDH1  and ALDH2  had no effect on cell proliferation 
and sphere-forming ability in HCC cells, it is thought 
that DSF exerts its anti-HCC function in an ALDH-
independent manner. 
 Although HSCs tightly control intracellular ROS 
levels to maintain long-term self-renewal and survival, 
the activation of the p38 MAPK upon an elevation in 
ROS levels resulted in the exhaustion of HSCs［54,55］. 
TICs usually exhibit lower intracellular ROS level than 
corresponding non-TICs［56］, and lower ROS levels 
in TICs result in inferior chemo-sensitivity and radio-
sensitivity［57］. Previous studies showed that DSF 
activates the ROS-p38 MAPK pathway and thereby 
suppresses TIC function［58］. We also confirmed that 
EpCAM＋ HCC cells contained lower ROS levels than 
EpCAM－ cells and that exposure to DSF activated the 
ROS-p38 MAPK pathway in these cells （Fig. 5）. Of 
importance, the treatment of EpCAM＋ HCC cells with 
NAC canceled p38 activation. Moreover, SB203580, an 
Fig. 5 Activation of the ROS-p38 MAPK pathway in 
HCC cells treated with DSF. （A） Flow cytometric 
analysis showed an increase in intracellular ROS 
concentrations after DSF treatment. （B） Cells treated 
with DSF were subjected to Western blot analysis.
A
B
Fig. 6 A proposed model for the effect of DSF in targeting 
tumor-initiating HCC cells.
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